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Essential requirements for setting up a stem cell
processing laboratory
T Leemhuis1, D Padley2, C Keever-Taylor3, D Niederwieser4, T Teshima5, F Lanza6, C Chabannon7, P Szabolcs8, A Bazarbachi9,
MBC Koh10,11 on behalf of the Graft Processing Subcommittee of the Worldwide Network for Blood and Bone Marrow Transplantation
(WBMT)
The Graft Processing subcommittee of the Worldwide Network for Blood and Marrow Transplantation wrote this guideline to assist
physicians and laboratory technologists with the setting up of a cell processing laboratory (CPL) to support a hematopoietic stem
cell transplant program, thereby facilitating the start-up of a transplant program in a new location and improving patient access to
transplantation worldwide. This guideline describes the minimal essential features of designing such a laboratory and provides a list
of equipment and supply needs and staffing recommendations. It describes the typical scope of services that a CPL is expected to
perform, including product testing services, and discusses the basic principles behind the most frequent procedures. Quality
management (QM) principles specific to a CPL are also discussed. References to additional guidance documents that are available
worldwide to assist with QM and regulatory compliance are also provided.
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INTRODUCTION
This report is intended as a guide for laboratory professionals
tasked with setting up a cell processing laboratory (CPL) to
support a new hematopoietic stem cell transplant program;
especially in a region or country with limited resources. It
describes the essential features of a laboratory’s design and
setup, provides basic processing principles and quality manage-
ment (QM) guidelines and references additional guidance docu-
ments available worldwide. The Graft Processing subcommittee of
the Worldwide Network for Blood and Marrow Transplantation1
wrote this guideline to help physicians and laboratory technolo-
gists establish and run a CPL that will support either an
autologous or allogeneic hematopoietic stem cell transplant
program, thereby improving patient access to transplantation as
a potentially curative modality of treatment.
We started with the assumptions that these guidelines will be
used for starting a laboratory that will only produce mini-
mally manipulated products, as defined by the US Food and Drug
Administration2 and the European Union.3 We also assumed:
(1) the availability of a clean, temperature-controlled and
securable environment, with reliable electricity; (2) the laboratory
is located in reasonably close proximity to the clinical site where
patients would be treated and where the donor cells would be
collected; (3) that the lab would be able to purchase supplies
suitable for clinical use; (4) that staff would have at least a basic
understanding of medical laboratory practices, as various labo-
ratories will already be part of the hospital infrastructure; and
(5) an understanding of the general principles of maintaining a
clean and safe medical laboratory.
The primary objectives for laboratories supporting an
autologous-only transplant program are to provide secure storage
for the stem cell graft and other cellular therapy products and to
adequately characterize the content of the cellular therapy
product for the physicians overseeing patient care. Support for
an allogeneic transplant program would additionally require the
lab to provide RBC and plasma-depletion services and be
prepared to thaw and infuse cord blood products. The need for
labeling and product tracking and transportation to and from the
hospital is required for all product types.
This guidance document is intended to assist with setting up a
CPL that provides safe and effective cellular therapy product
processing, storage and graft characterization services for a
hematopoietic stem cell transplant program or programs. Many
additional guidance documents, published literature and other
useful on-line resources available internationally from relevant
professional societies and governmental agencies are referenced
throughout.
We emphasize that financial planning is a crucial aspect in
setting up a laboratory and should be a core consideration from
the outset. It continues to be a critical component once the
laboratory is established in terms of revenue generation as well as
maintenance and processing costs. These will all impact upon the
running costs of the hospital and ultimately on the cost of SCT
both for the country and to the patient. The variability of health-
care systems, modes of funding and payment as well as
infrastructure support makes it difficult to offer any single model
of financial planning other than to emphasize its critical
importance.
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Laboratory design and physical plant requirements
When first establishing a transplant program, a relatively small
dedicated space or even a clearly defined shared space is typically
sufficient for a CPL, provided product safety risks such as cross
contamination or product mix-ups are taken into consideration
with the design and location.
The laboratory should be located as far from potential
contaminants as possible and in as clean a space as possible.
Sharing space or equipment with microbiology laboratories, or
laboratories that utilize radioactive isotopes should be avoided, as
that arrangement may increase the risk of product contamination.
When sharing space with a hospital or clinic lab, locating the CPL
adjacent to the Blood Bank has a number of advantages. As the
equipment needed, procedures used, product safety focus and
staff training needs are similar, there is an opportunity to share
more than just the physical space. Standard hospital electrical
supply is sufficient; however, a backup power generator and/or
access to an uninterruptible power source is highly desirable in
case of power outages, especially for equipment used for cellular
therapy product storage. A lockable file cabinet or another system
for storing facility documents and product records securely is
required. A sink and water supply for hand washing and cleaning
within the laboratory or nearby is important. Dedicated work-
station(s) in a clean environment with restricted controlled
access and away from potential contaminants are essential. Each
workstation should contain a biosafety cabinet (1.2–1.8 m),
approximately 2 m of counter space, a plasma extractor and a
centrifuge, with access to a refrigerator, −70 °C (or colder)
freezer and a microscope nearby. The number of workstations
needed will depend on the number of products anticipated to be
processed in a day and on the number of staff available for
processing. It is important to limit each workstation and each staff
member to the processing of one product at a time. Because
access to liquid nitrogen (LN2) may pose a challenge in certain
regions, this document focuses on −70 °C or colder product
storage in mechanical freezers. Storing products in a mechanical
freezer requires a consistent, reliable electrical power source; so if
the likelihood of power interruptions is high, it is safer to store the
products in an LN2 freezer. If products are to be stored in tanks
requiring LN2, the facility must be designed to facilitate regular
delivery of LN2 supply dewars. The space containing the LN2
storage tanks and supply dewars should be separate from the
processing laboratory and needs to have sufficient air handling
capacity to maintain safe levels of oxygen during the times when
the LN2 tanks are filling. An oxygen sensor that alarms when levels
are dangerously low is highly recommended.
It is crucial that the need for facility cleaning and waste disposal
is not overlooked during the design phase. Biohazardous waste
can usually be disposed of according to hospital practices.
Uncluttered, readily cleanable and preferably, impervious work
surfaces, availability of adequate space for raw material sto-
rage and separation of waste materials and sharps should be part
of the design plan. All cleaning protocols and schedules should be
clearly outlined and validated. Introduction of potential airborne
contaminants into the laboratory should be minimized by process
controls such as limiting access to laboratory personnel only and a
design that avoids the need to deliver supplies and medical gas
cylinders directly to the processing space. Temperature and
humidity of the laboratory space should be controlled to the
extent possible to maintain proper storage conditions for reagents
and supplies, to ensure optimal performance of sensitive
electronic equipment and for employee comfort. In addition,
warm, humid conditions for extended periods favor the growth of
contaminants, such as fungi and moulds.
Equipment
The equipment requirements for a CPL are fairly minimal. Table 1
lists the equipment needed in three categories: Required,
Desirable, (nice to have), and Shared (equipment that because
of expense, maintenance considerations and low volume use
could be shared with another laboratory within reasonable
proximity). Critical equipment should be maintained and cali-
brated on a regular basis. Backup equipment should be identified
when only one device is in use by the laboratory. Each piece of
equipment, including that designated as backup equipment,
should undergo qualification and validation before use.4 If an
uninterruptible emergency power supply is available, the critical
pieces of equipment should be connected to that supply. Product
storage and supply storage refrigerators and freezers are
particularly critical and must have a reliable power source. In
addition, refrigerators and freezers that store patient products or
critical reagents and supplies should be in a secure location, with
only authorized personnel having access, and if at all possible,
have full-time temperature monitoring with alarm systems that
notify key personnel when temperatures are out of range. Storage
devices need to be monitored by lab staff at least once or twice
each day. Mechanical freezers ultimately will fail, therefore access
to a backup freezer or another contingency plan in the event of a
freezer outage is highly recommended. Adequate backup liquid
(or vapor) nitrogen storage capacity should also be considered, as
well as planning for separate quarantined product storage
capacity.
Supplies and reagents
A partial list of supplies and reagents that will be needed is
provided in Table 2. All product contact reagents need to be
sterile and of infusion-grade. All supplies need to be sterile and
disposable; used once and discarded. Reagents can be dispensed
into single-use containers before use in order to minimize waste.
All reagents and supplies need to be inspected before use and
stored in controlled (and monitored) environments, separate from
non-clinical, potentially harmful research reagents, and it is
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important to document the specific lot numbers used during
processing. Such careful materials management requires signifi-
cant effort but contributes greatly to error prevention and overall
product quality.
Personnel
Education and training of staff is critical for the establishment and
operation of a CPL. Processing products for cryopreservation is not
a highly technical operation; however, attention to detail, strict
aseptic technique, a quality focus and consideration of the
importance of each product for the patient are key factors for
success. Staff with formal education in a laboratory-based
discipline, and preferably with some experience in clinical
hematology and/or blood banking, are most suited for the work
that is required.
Although most processing operations for a start-up program can
be accomplished by a single staff member, a minimum of two
trained laboratory technicians is required, one of whom could be
cross-trained from another laboratory. This is not only to cover
absences due to illness or leave but also for planned or unplanned
long working hours and the variability of workload in transplant
programs. A second individual is also essential to maintain quality
through verification of procedure steps and double checks of
product and patient identity. Mistakes can be fatal for the patient;
having two people reviewing records before product release
minimizes the likelihood that a mistake will occur. It is also
essential that one person works with only one stem cell product at
any one time to prevent mix up of samples. If the laboratory is
within a hospital, a staff sharing arrangement with the blood bank
or other clinical laboratory can be a cost-effective strategy for
processing staff backup.
Quality control testing of the product can be performed by the
cell processing staff if necessary, but it may be more cost effective
to contract with the hospital’s Microbiology, Flow Cytometry and/
or Hematology laboratories that perform these tests routinely.
Either way, the staff performing quality control testing must be
trained in the unique aspects of testing hematopoietic progenitor
cell (HPC) products. The written agreements need to specify
regulatory requirements for the contracted testing lab as well as
procedures for timely result reporting.
We also recommend hiring or sharing part-time staff that do not
have processing responsibilities to focus on Quality Assurance and
Regulatory tasks, such as reviewing charts, inspecting raw
materials, releasing products for infusion, doing process improve-
ment projects and performing internal regulatory compliance
audits. The time required for record review, product release and
other non-technical duties can easily exceed the time spent
processing products. The person responsible for the quality
program needs to be familiar with the principles of QM as well
as the local government’s regulations and must also understand
the technical aspects of the laboratory in order to design and
maintain an effective quality plan that improves outcomes and
reduces errors. This person needs to report quality parameters to
the clinical program and to the hospital’s overall QM personnel
regularly and should be supervised either by the clinical
program director or by someone in the hospital’s compliance
office.
It is important for the processing laboratory to have a close
relationship with the clinical transplant program and be viewed
as an integral part of the transplant team. The laboratory should
be represented at clinical transplant planning meetings so that
expected collection dates and transplant dates are clearly
communicated, and the laboratory staff has access to engraftment
data that can and must be correlated with the stem cell collection
data (CD34+ cell count, total nucleated dose and viability). This
will give an assurance that the clinical outcomes match the
reliability of processing and can also serve as an indicator if
processing standards are sub-optimal. Often, one of the transplant
physicians serves as the Medical Director for the CPL, providing
oversight and guidance for laboratory staff and serving as a
consultant for the less experienced physicians treating transplant
patients. We recommend that this person should not be in charge
of daily laboratory operations however; rather there should be a
designated supervisor or manager in charge of staff scheduling
and ensuring standard operating procedures are followed. It is
also imperative that the clinical transplant program confirms with
the CPL that the products are available before beginning the
patient’s conditioning regimen. This is especially important in
newly established facilities where document control systems may
be less well tested and cryopreservation potentially less reliable.
Processing principles
The CPL’s primary role in supporting an autologous transplant
program is to preserve cellular therapy product viability during
storage and to prevent the introduction of microbial contamina-
tion at all stages of processing. The autograft is collected before
the patient receives high-dose therapy,5 and depending on the
disease and treatment plan, cellular therapy products may need to
be stored from several days to a few weeks, months or even years.
Storage at 2–8 °C maintains acceptable HPC viability only for
relatively short periods of time (48–72 h),6 therefore cryopreserva-
tion is required for longer storage periods. Ideally products should
be cryopreserved as soon as possible after collection. However,
overnight storage is also acceptable if the product is kept
refrigerated (2–8 °C). If product cellularity exceeds 2 × 108 cells
per mL or contains a high proportion of mature granulocytes,
Table 2. Minimal supplies needed to start a cell processing lab
Miscellaneous laboratory supplies
Cryobags (for example: 50; 250; 500mL) Transfer packs (300; 600mL) Syringes (1, 3, 10, 30, 60mL)
Safety needles; couplers Spike to needle, spike to spike
adapters; stopcocks
Alcohol swabs, iodine swabs, syringe
caps, sterile swabs
Labels, laminating tags; zip ties 15, 50, 175mL conical tubes Pipettes (1–50mL)
Biohazard sample bags Tube racks Pipette tips
Cryovials, microtubes Biohazard bags; sharp containers;
garbage bags; trash can
Dry ice
Sterile overwrap bags
Sample reagent list (will vary depending on products and services offered)
DMSO Plasmalyte (or equivalent) ACD-A
Human serum albumin Hetastarch Heparin
70% IPA; bleach; bactericidal and fungicidal detergent Flow cytometry reagents Trypan blue
Abbreviations: ACD-A= acid citrate dextrose solution A; DMSO=dimethyl sulfoxide; IPA= isopropyl alcohol.
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dilution with concurrent plasma may better preserve viability. HPC
and Apheresis products may be more vulnerable to temperature-
related cell loss during liquid storage than BM products.7 An
adequate amount of anticoagulant should be added to avoid cell
aggregation if storing or transporting the product for longer
periods of time (24–72 h). The use of acid citrate dextrose is
recommended; heparin should be used with caution as it could
potentially exacerbate bleeding complications in thrombocytope-
nic transplant patients.
Most cryopreservation protocols involve (stepwise) volume
reduction, addition of a cryoprotectant solution, controlled rate
(slow) freezing and storage at vapor-phase LN2 temperatures
(⩽−160 °C). Although the procedures for performing these steps
are far from standardized, strict adherence to aseptic technique is
universally required. In a start-up situation, with limited resources,
it is possible to maintain cellular therapy product viability using a
⩽−70 °C mechanical chest freezer instead of a programmable
controlled rate freezer and LN2 storage freezer.
8–10 Cellular
therapy product stability can be maintained for several months
at the warmer temperature by using a cryoprotectant consisting of
6% hydroxyethylstarch and 5% dimethyl sulfoxide (DMSO) and
human albumin.10 For longer-term storage (years) cryopreserva-
tion with a final concentration of 10% DMSO and storage in liquid
or vapor phase nitrogen is still the preferred and most widely used
methodology, as there has been some indication of a fall in GM-
CFU (granulocyte macrophage colony-forming unit) colonies after
1 year of storage at − 80 °C.11 Protection from temperature
fluctuations is an important consideration. Products stored in
liquid-phase LN2 (−196 °C) are better protected from temperature
fluctuations but are at increased risk for bag breakage at thaw and
cross-contamination from other products. It is recommended that
they should be wrapped in an overwrap bag before or just after
cryopreservation and stored in metal cassettes to protect them
from damage. Also, it may be prudent to cryopreserve products in
at least two bags to reduce the risk of catastrophic product loss in
the event of a bag breaking. Cryopreserving small volume retain
vials along with the product allows for testing the product
integrity (viability; sterility) either before or after infusion in the
event of an adverse reaction or processing deviation.
Cell viability during freezing and storage can be maintained
using either 10% DMSO or a combination of 5% DMSO and
hydroxyethylstarch as cryoprotectants.10,12–14 Recent reports in
the literature describe fewer adverse reactions to infusion with
lower DMSO concentrations.15 Detailed cryopreservation proto-
cols are available from published manuscripts and book
chapters16–18 and from the International Society of Cellular
Therapy (ISCT) and AABB professional association websites19,20
and from their members. In general, it is beneficial if the cell
suspension and cryoprotectant solution are chilled before mixing,
the cryoprotectant solution is added slowly and with gentle
agitation only and the exposure time to DMSO before freezing is
minimized. Advanced preparation is therefore essential. The
products should be cryopreserved in bags, not tubes, so that
the cryopreservation media can be added and the cells distributed
in a closed system, with much less risk of contamination. A start-
up CPL should demonstrate their chosen cryopreservation
protocol results in an acceptable postthaw viability (⩾≈70%)
before performing their first transplant, as part of a process
validation protocol. Once established, the laboratory should
routinely monitor postthaw viability and watch for adverse
trending as part of their quality plan. Written processing
instructions (standard operating procedures), data capture work-
sheets, labels, result reporting and clinical site communication
documents and equipment quality control forms all need to be in
place before processing the first product, so that thorough
documentation of each processing step can be filed indefinitely as
part of the patient’s record.
In contrast to the freezing process, the products should be
thawed rapidly, in a 37 °C water bath if possible, but without
letting the product warm past ambient temperature before
infusion. Exposure time to DMSO after thawing should be
minimized to avoid cell death.21 Special attention should be paid
to minimizing the chances of contaminating the product during
the thaw process. Thawing products in a sterile overwrap bag not
only protects the product from contamination but also allows for
product recovery in the event a bag breaks during the thaw. Most
often, products that are directly thawed are done so in close
proximity to the patient, requiring the transport of the product
and equipment needed for thawing by laboratory personnel and
the presence of laboratory staff throughout the infusion.
Inspecting bag integrity before transport and bringing supplies
needed in case of bag breakage to the clinical site is highly
recommended.
Some laboratories use a dilution method and removal of the
supernatant along with most of the DMSO by centrifuging the
product.15,22 This method greatly reduces the incidence and
severity of adverse reactions. A survey of laboratory practices
conducted by EBMT indicated an effect of the amount of DMSO
infused with a product and toxicity reactions at infusion, with the
lowest rate of toxicity seen after infusion of products from which
DMSO was removed by washing.23 Such wash methods must be
performed in the laboratory. However, with DMSO removed,
postthaw viability at refrigerator temperatures is maintained for
longer periods of time making this a feasible approach. The
thawing method chosen must consider logistical issues such as
the proximity of the laboratory to the infusion site and the need
for good communication between the laboratory and the infusion
team to minimize the time between thawing and infusion. For all
methods, products should be thawed one at a time in case of an
adverse reaction to infusion requiring treatment before subse-
quent infusions. If DMSO cannot be removed, the volume per kg
infused at a single setting should be considered, especially if a
large number of bags are infused. Infusion of a large volume of
DMSO (>1mL/kg) can cause severe hemodynamic stress and
infusion-related hemolysis, therefore close monitoring of vital
signs, body weight and urinalysis is required.24 DMSO toxicity is
rarer with cord blood transplants, where the infusion volume is
low; however, direct infusion of thawed cord blood products is not
recommended. Only appropriately trained personnel—either CPL
technologists or transplant ward nurses—should be authorized to
thaw and administer autologous hematopoietic stem cell
products.
There are several other immunological and non-immunological
infusion toxicities to be aware of, and prepared for, when infusing
cell therapy products. The Circular of Information for the use of
cellular therapy products, an effort from multiple organizations,
including AABB, ISCT and ASBMT,24 is an excellent resource for
understanding the more common types of adverse reactions that
can and do occur.
All cryopreservation and thawing protocols result in some
product loss; thus it is best if allogeneic products can be infused
without cryopreservation whenever possible. It can sometimes be
logistically challenging to coordinate the timing of the allogeneic
collection from a volunteer donor so that the product is available
for infusion just as the patient is ready to receive the cells. It may
occasionally be necessary to cryopreserve an allogeneic donation,
but this is not recommended as standard practice, unless the
physician wishes to limit the cell dose infused fresh and requests
that ‘extra’ HPC or donor T cells be cryopreserved for future use.
Many allogeneic products can be infused directly, without
processing other than sampling for sterility and performing cell
counts and determination of CD34+ cell content. However, the
laboratory needs to be prepared to perform either RBC depletion
or plasma depletion on ABO-incompatible BM products and
plasma depletion of mobilized peripheral blood products. There is
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generally not a need for depleting additional RBC from a
mobilized apheresis product as the RBC content is already quite
low; however, BM products with a major ABO incompatibility to
the recipient’s blood type cannot be infused safely without
significantly reducing the RBC content. There are a few ways to
accomplish the RBC depletion; the most common and the
simplest way being a gravity sedimentation procedure after
adding hetastarch to the BM to agglutinate the RBC and cause
them to settle more rapidly than the WBC.25,26
Patients receiving minor ABO incompatible transplants face a
risk of hemolysis from the infusion of incompatible plasma
contained in the product, particularly with marrow products.
Depending on the amount of donor plasma present, the donor’s
Isoagglutination titers and donor/recipient blood types, plasma
depletion may or may not be required for minor ABO-mismatched
allogeneic products to prevent anti-ABO antibodies in the product
from lysing the recipient’s erythrocytes.26 This can be accom-
plished with a single high-speed centrifugation and removing the
majority of the plasma before infusion. A second centrifugation
(wash procedure) can be helpful if the donor has a particularly
high titer anti-ABO antibody (⩾1:256).27
If supporting an allogeneic program that utilizes unrelated
donor products from around the world, the processing lab is often
responsible (in most regulatory frameworks) for making sure that
the donor screening and donor testing results confirm donor
eligibility. Donor eligibility rules vary internationally, but most
involve testing the donor within a few weeks (typically 4) of
donation for the presence of infectious agents, such as HIV 1
and 2, HTLV 1 and 2, Hepatitis B, Hepatitis C, West Nile Virus and
Syphilis, in a concerted effort to prevent the spread of infectious
disease from donor to recipient. Additional testing for other
infectious disease agents may be required depending on
individual countries, range of infectious diseases and regulatory
frameworks. The processing laboratory is frequently not involved
in the testing itself; nonetheless, it should be part of standard
operating procedure that the infectious disease test results are
negative and up to date before releasing a product for infusion. If
a clinical decision has been made to infuse the product despite a
positive or out-of-date test result, the laboratory is then
responsible for labeling the product as a non-conforming product
and making sure all are aware of the risks involved. In addition, it
is important for the CPL to be aware of the infectious disease
marker results before receipt of any product into the CPL so that
appropriate labeling is applied and so that products are stored in a
manner to prevent release before appropriate approvals have
been obtained. All products must be handled in a manner to
reduce risks of cross-contamination and ensure staff safety.
Regardless of whether the laboratory supports an autologous or
an allogeneic transplant program, strict product labeling, trans-
portation and product-tracking systems and procedures need to
be in place from the beginning through to infusion to prevent
product mix-up errors and to maintain product integrity while
delivering the product to the patient. Complete traceability is
essential. The laboratory may be storing products from many
patients in the same freezer; it is vital that labeling is clear and
that product and patient identity double checks are in place
at the time the product is received into the laboratory, placed
into storage and removed from storage for infusion. Insulated
coolers and gel packs are required to transport fresh products at
cool temperatures. Transport of cryopreserved products from the
lab to be thawed at the bedside should occur minimally on
dry ice if the clinical site and hospital are not immediately
adjacent in order to minimize the time between thaw and
infusion. Products could be thawed (one at a time) in the
laboratory and transported to the hospital in a cooler if products
can still be infused within 15–20min of thaw, or if the
cryoprotectant is removed, products may be stored at refrigerator
temperatures for up to 3 h.
If sufficient resources are available, the implementation of the
ISBT 128 labeling standard is highly desirable from the start.28 The
financial investment is likely to be rapidly offset by the decrease
in the workload that is associated with the design of custom
and locally made labels that are compliant with national and
international requirements. Whenever possible, barcodes and
barcode readers should be used instead of handwritten labels.
Even though most donors are tested for the presence of several
common infectious diseases before donating, cellular therapy
products are potentially infectious. It is essential that staff are
provided with personal protective equipment such as lab coats,
gloves and safety glasses and properly trained to use universal
precautions to protect themselves from possible infection and to
protect the products from cross-contamination. Lab design,
engineering controls and staff training should focus on reducing
the risk of product contamination to prevent the introduction or
spread of infectious disease in severely immunocompromised
transplant patients.
Cellular Therapy Product Characterization/Quality Control Testing
BM contains a wide range of cell numbers and cell types and
responses to agents used to mobilize HPCs to the peripheral blood
vary, especially for the autologous donor. Therefore, it is
imperative that the laboratory provide the patient’s physician
with cell count data and CD34+ cell count data so they can assess
the potential of the cellular therapy product to engraft before
initiating conditioning therapy. The total leukocyte count is
important as is a calculation of the mononuclear cell count
(manual differential or flow differential) and a blast cell count, as
the number of immature myeloid cells correlates with engraft-
ment better than the total cell count.29,30 However, the total CD34
cell count is currently the best available predictor of engraftment,
especially for PBSC grafts while the total nucleated cell count is
often still used for marrow grafts.31 Although the minimum
number of CD34+ cells required for engraftment has not been
firmly established, most investigators accept a minimum of 2 × 106
CD34+ cells/kg for optimal engraftment. When possible, higher
doses of 4–5 × 106 CD34+ cells/kg are preferred, as they are
associated with faster engraftment, reduced incidence of infection
and reduced need for transfusions. Enumeration of peripheral
blood CD34 counts during mobilization is useful for planning the
apheresis collections necessary to obtain these grafts. Hematology
analyzers can provide total cell count information, or these counts
can be obtained with reasonable accuracy by making slides to
perform a differential and manually counting cells in a hemocyt-
ometer using a microscope. The lab could purchase a small
analyzer; however, given the low number of samples and
requirements for calibration and maintenance of this piece of
equipment, it may be more cost effective for a start-up lab to send
the sample to the hospital’s hematology lab for analysis. A more
specialized flow cytometry analyzer is required for CD34+ cell
detection. Flow cytometry can also be used to determine
mononuclear cell content and viability. CD34+ cell enumeration
is most accurately performed using a multiparameter definition of
progenitor cells based on their light scatter characteristics, dim
expression of CD45 and CD34 expression. References as to how to
perform these tests are readily available through the professional
networking opportunities offered by ISCT, Foundation for the
Accreditation of Cellular Therapy (FACT) and AABB. Adhering to
published guidelines for the CD34 analysis is very important as the
stem cells represent a small percentage of the total number of
cells and must be carefully enumerated.32–35 The use of a ‘single
platform’ method for enumeration of viable CD34+ cells is
recommended for many low-volume start-up laboratories.33,34
For both tests, the lab would need to purchase a dilution buffer,
sample tubes, syringes and needles, a viability dye and fluores-
cently labeled monoclonal antibodies to CD34 and to CD45 (and
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to CD14 if assessing mononuclear cells), although there are
currently kits available that contain all the necessary reagents for
the ‘single platform’ method. A small centrifuge would also be
required for the CD34 testing.
A sample for cellular therapy product sterility testing for aerobic
and anaerobic bacteria as well as fungus is required by most
regulatory agencies to be taken before product infusion. This
testing is best done in collaboration with a hospital microbiology
laboratory that can also provide antibiotic sensitivity testing on
any organisms found. Line infections or bacteremia at the time of
collection are the most common sources of contamination for
autologous peripheral blood products. Likewise, during BM
harvest, skin contaminants are not infrequently introduced.
Therefore, we recommend testing HPC products before and after
processing, just before either infusion or cryopreservation to
facilitate investigation of the cause of any identified contamina-
tion. This is especially important in a start-up situation, as the
laboratory has to know that they are not introducing
contaminants.
Many institutions perform a postthaw viability assessment on a
retain vial, using either trypan blue or 7-aminoactinomycin D, as
part of their product release procedure for cryopreserved
products. Others monitor the postthaw viability of the product
at the time of transplant and then look for adverse trends or
outliers. Both are worthwhile product-testing objectives.
A typical HPC product testing plan is provided in Table 3. The
testing plan should be designed to prove the product’s identity,
purity, potency and (most importantly) safety. Additional, more
complex testing may be needed to ensure the safety and potency
of more specialized cell therapy products, and it may be necessary
to test the product before and after processing to be sure that the
processing is working correctly. Note that all product release
testing for fresh infusion products needs to be performed
immediately so that the product can be infused in a timely
manner. Products can still be infused if they do not meet
predetermined acceptance criteria, but only if there is an urgent
medical need and only with documentation of the transplant
physician's and/or Medical Director's approval.
Product release
Standard operating procedures or policies must be in place
defining the criteria that must be met for a product to be released
from the laboratory for infusion. Staff releasing the product must
confirm that all criteria are met; or if they are not met, that the
required approvals and notifications have been obtained from the
transplant physician or Medical Director. Ideally, final review of
processing records and approval for product release should come
from laboratory management and/or from ‘independent’ QM staff
not directly involved in the processing operations, as is done in
pharmaceutical production. A final review of processing records
by laboratory management is always required.
Quality plan essentials
Finally, each of us wishes to emphasize the importance of starting
the planning for building a processing laboratory by writing a
Quality Plan specific to the laboratory. A quality plan summarizes
and references the organization’s policies, procedures and
practices related to the day-to-day operation of the facility and
in the case of emergency. There are many resources available for
guidance through the FACT and AABB, and others,36,37 but
minimally the Quality Plan needs to describe the policies and
procedures that will be used to ensure product integrity,
prevent contamination from the environment, prevent cross-
contamination from other products and prevent products going
to the wrong patient. Starting with a description of staff safety and
disaster planning procedures, a useful quality plan also describes
the organization’s minimal staff qualifications, staff training and
competency assessment procedures, document control, record
retention, materials management, process validation, process
control and event reporting procedures, including a system for
corrective and preventive actions. The Quality Plan needs to
summarize and reference policies and procedures for handling
products with positive microbial culture results and describe
procedures for how to quarantine such products, document
urgent medical need and release for infusion only with physician's
Table 3. Quality control testing for HPC products
Attribute Test method Specification





Certified laboratory Negative (exclusive
of CMV)a
Infusion volume Measurement ⩽ 20mL/kg/infusion













CD34+ cell count Flow cytometry ⩾ 2 ×106/kg
CD3+ cell count (if
allogeneic)
Flow cytometry As measured
Viability (pre-freeze) Flow cytometry ⩾ 80%
Sterility Bacterial culture No growth




Abbreviation: HPC=hematopoietic progenitor cell. aInfectious disease
testing of autologous products is not universally required worldwide.
Consult national regulations.




Organization Organizational charts; reporting structures,
inter-institutional relationships
Personnel Human resources policies; job descriptions;
personnel qualifications, training and
competency




Floor plans; cleaning schedules; mechanical







Equipment Qualification; calibration; maintenance;
cleaning schedules
Process controls Change control; methods to prevent mix-
ups and cross-contamination; process
validation; product release; quarantine
storage; product tracking; label control
Documents and
records
Standard operating procedures; document





Deviation and adverse event reporting;




Donor eligibility; product testing; outcome
analysis; audits
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approval. The Quality Plan should also describe procedures for
data collection and outcome analysis (especially time to engraft-
ment);38 so that problems can be detected quickly and resolved.
Most regulatory agencies now require that a quality plan include
regular analysis of its performance, including correlation with
clinical parameters like engraftment. Planning for these activities in
advance enables good decisions on what supplies and equipment
to purchase, what space to use or to build, staff to hire and so on.
Table 4 describes the subject headings present in a typical
quality plan for a CPL. In the early stages of starting a laboratory,
the quality plan could be made up of mostly policies or policy
statements as guiding principles, and as the program matures, the
scope and detail of the quality plan can grow as well. Having a
simple QM plan from the start allows the laboratory to obtain
authorizations from governmental agencies and competent
authorities and pave the way for accreditation by FACT–Joint
Accreditation Committee ISCT (Europe)-EBMT (JACIE), AABB39,40 or
a similar organization. Although outside the scope of this
guidance document, the International Netcord Foundation41 and
FACT have collaborated to provide accreditation standards and
guidance for cord blood banking operations.
Regulatory compliance
Regulatory compliance requirements will vary greatly between
countries. In general, a solid quality plan that addresses all local
regulations, adherence to the principles of that plan and
documentation to support that adherence will likely allow the
laboratory to comply with the regulatory frameworks.
FACT, AABB, JACIE, Netcord, The Alliance for Harmonization of
Cellular Therapy Accreditation and others all have many resources
available to assist facilities with regulatory and accreditation
issues. We wish to recommend, however, that it is best to focus on
product quality and patient safety first and foremost. Regulatory
compliance will follow quality work.
CONCLUSION
This paper describes the essential elements and considerations in
starting a stem CPL. There is considerable room for improvement
and addition as resources become available or as the transplant
program evolves. Table 1 highlights a list of equipment that is
required vs equipment that is desirable or can be shared. This is
certainly one area for development as the transplant pro-
gram matures and expands. Additional personnel in addition to
the minimum of two would also be an important consideration to
handle the greater volume and complexity of work and to allow
for independent checks as well as verifications for product release
to minimize potential conflict of interest issues.
More specialized equipment may also be required for more
complex stem cell processing, such as T-cell depletion. Another
area of improvement is the introduction of robust and efficient
information technologies to handle greater volumes of work and
to minimize paper-based errors. Information technologies also
improve traceability and greatly help to support a comprehensive
QM plan as well as document-tracking systems. This will also
complement the use of barcode printers and readers and aid in
the adoption of international nomenclature, such as ISBT 128.
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